Featured Articles

Novo Nordisk A/S and KBP Biosciences PTE., Ltd. announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular…
Read More...

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) for the treatment of adult patients with metastatic…
Read More...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, announced that global…
Read More...

AbbVie announced that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class…
Read More...

Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon…
Read More...

Positive results from the T2NOW Phase III trial demonstrated significant reduction in A1C, a marker of average blood sugar, for patients treated with Forxiga (dapagliflozin) compared…
Read More...

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is the first CTDMO (contract testing, development and manufacturing organization) to offer…
Read More...

GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) for the prevention of RSV…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR),…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a supplemental new drug…
Read More...

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for LITFULO (ritlecitinib) to treat adults and adolescents 12 years of age and older with…
Read More...

BioNTech SE and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT166 for…
Read More...

AbCellera announced that it has entered into a strategic collaboration with Incyte to discover and develop therapeutic antibodies in oncology. “We are excited to partner with Incyte,…
Read More...

Takeda announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous (SC)…
Read More...

Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (COMIRNATY 2023-2024 Formulation) for…
Read More...

Pfizer Inc. and BioNTech SE announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for…
Read More...

Embark Laboratories announced that Novo Nordisk has acquired Embark Biotech, including its lead metabolic program, and has entered a three-year research and development collaboration to…
Read More...

Roche announced that Tecentriq SC (atezolizumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain. It will be provided by the…
Read More...

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury (remdesivir) with no dose…
Read More...

AstraZeneca and Merck, known as MSD outside of the United States and Canada, announced that LYNPARZA in combination with abiraterone and prednisolone (abi/pred) has been approved in…
Read More...